Journal: Nature Communications

Article Title: Reduced hepatic bradykinin degradation accounts for cold-induced BAT thermogenesis and WAT browning in male mice

doi: 10.1038/s41467-023-38141-0

Figure Lengend Snippet: a Free fatty acids (FFAs) levels in the liver of male WT mice exposed to 25 °C (RT) or 4 °C (Cold) for different amounts of time in the absence of food and water. b PREP activity in primary hepatocytes treated with 0, 0.75 or 1 mM oleic acid (OA) for different amounts of time. c BK levels in cell lysates and the culture medium of primary hepatocytes treated with 0, 0.75 or 1 mM OA for 6 h. d BK levels in cell lysates and the culture medium of primary hepatocytes infected with (+ Ad-PREP) or without (–Ad-PREP) Ad-PREP in the absence (–OA) or presence (+OA) of 1 mM OA for 6 h. e BK levels in cell lysates and the culture medium of primary hepatocytes treated with 0, 10 or 50 μg/mL S17092 for 6 h. f BK levels in cell lysates and the culture medium of primary hepatocytes transfected with (si- Prep ) or without (si-NC) Prep siRNA for 72 h. g , h PREP activity ( g ) and BK levels in cell lysates and the culture medium of primary hepatocytes ( h ) treated with (+UDCA) or without (–UDCA) ursodeoxycholic acid (UDCA) in the absence (–OA) or presence (+OA) of 1 mM OA for 6 h. For a , n = 7 in each group. For b and c , n = 4 or 5 in each group. For d , n = 4–6 in each group. For e , n = 6 in each group for hepatocytes; n = 5 (medium 0 μg/mL S17092) and 4 (medium 10 μg/mL, 50 μg/mL S17092) in each group. For f , n = 4–6 in each group. For g , n = 6 in each group. For h , n = 5 or 6 in each group for hepatocytes; n = 5 in each group for medium. Mean±SEM are representative of at least two independent experiments ( a ) or at least three independent experiments ( b–h ); two-tailed unpaired Student’s t -test ( a ), ordinary one-way ANOVA with Dunnett’s test ( b, c, e, f ), ordinary one-way ANOVA with Tukey’s test ( d ), ordinary two-way ANOVA with Tukey’s multiple comparisons test ( g, h ). Source data are provided as a Source data file.

Article Snippet: OA (Sigma, USA), s17092 (Sigma, USA) and UDCA (MCE, China) were added at the indicated concentrations in DMEM without FBS on the second day following hepatocytes isolation.

Techniques: Activity Assay, Infection, Transfection, Two Tailed Test

Journal: Nature Communications

Article Title: Hepatic thyroid hormone signalling modulates glucose homeostasis through the regulation of GLP-1 production via bile acid-mediated FXR antagonism

doi: 10.1038/s41467-022-34258-w

Figure Lengend Snippet: a – c The percentage of individual BA in the gallbladder bile ( a ), ileum ( b ) and feces ( c ) of MMI and MMI + T3-5d mice ( n = 5). d The percentage of individual BA in the ileum of Floxed and LTRβKO mice treated with PBS or T3 for 5 days ( n = 5). e – g The percentage of non-12α-OH FXR-antagonistic BAs, including T(α/β)MCA, (T/G)UDCA, and (T)HDCA in the gallbladder bile ( e ), ileum ( f ) and feces ( g ) of MMI and MMI + T3-5d mice ( n = 5). h The percentage of non-12α-OH FXR-antagonistic BAs in the ileum of Floxed and LTRβKO mice treated with PBS or T3 for 5 days ( n = 5). Means ± SEM are shown. P values were calculated by two-tailed unpaired Student’s t test. ns not significant. Source data are provided as a Source Data file.

Article Snippet: The cells were treated with BAs (100 μM, 24 h), including CDCA, TβMCA, HDCA (T2968, TargetMol) and UDCA (T0700, TargetMol), for GLP-1 measurement and RNA isolation.

Techniques: Two Tailed Test

Journal: Nature Communications

Article Title: Hepatic thyroid hormone signalling modulates glucose homeostasis through the regulation of GLP-1 production via bile acid-mediated FXR antagonism

doi: 10.1038/s41467-022-34258-w

Figure Lengend Snippet: a , b Correlation between free T3 levels and plasma active GLP-1 levels ( a ) or plasma insulin levels ( b ) in a cohort of euthyroid human study participants ( n = 30). c – f Association analysis of free T3 levels and fecal BA levels i n another cohort of euthyroid human study participants ( n = 19). Correlation of free T3 levels with 12α-OH/non-12α-OH ratios ( c ), (T)HDCA levels ( d ), (T/G)UDCA levels ( e ), and the levels of both (T)HDCA and (T/G)UDCA ( f ) in the feces of these human study participants. Pearson correlation and two-tailed t -test was performed for correlation analysis. Source data are provided as a Source Data file.

Article Snippet: The cells were treated with BAs (100 μM, 24 h), including CDCA, TβMCA, HDCA (T2968, TargetMol) and UDCA (T0700, TargetMol), for GLP-1 measurement and RNA isolation.

Techniques: Clinical Proteomics, Two Tailed Test

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Validation of the optimal working concentration and treatment of UDCA to inhibit FIPV proliferation. ( A ) CCK-8 assay for the effect of ursodeoxycholic acid on the activity of CRFK-PHBLV-N cells. ( B ) FIPV N gene level after the action of ursodeoxycholic acid. ( C ) Western blotting to detect the changes of FIPV N protein. ( D ) Gray scale of the FIPV N protein change analysis. ( E ) CRFK-PHBLV-N cells in FIPV IFA results graph. ( F ) CRFK-PHBLV-N cells in FIPV fluorescence intensity analysis. **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Biomarker Discovery, Concentration Assay, CCK-8 Assay, Activity Assay, Western Blot, Fluorescence

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Changes in FIPV N gene copy number and protein expression at different stages after ursodeoxycholic acid treatment. ( A ) Graph of different stages of treatment. ( B ) Graph of FIPV N gene copy number results in CRFK-PHBLV-N cells at different stages. ( C ) Graph of FIPV results in CRFK-PHBLV-N cells at different stages. ( D ) Grayscale analysis of FIPV in CRFK-PHBLV-N cells at different stages. ( E ) Negative staining electron micrograph of FIPV virus particles. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; and ns, not significant.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Expressing, Negative Staining, Virus

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Screening of signaling pathways associated with anti-FIPV infection after UDCA co-treatment based on transcriptomic data. ( A ) KEGG pathway enrichment analysis. ( B ) Differential gene volcano plot. ( C ) Correlation analysis of FIPV-UDCA 200 μg/mol co-treatment with antiviral gene expression. ( D ) IFN-β ELISA results in CRFK-PHBLV-N cells. * P < 0.05; ** P < 0.01; *** P < 0.001; and **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Protein-Protein interactions, Infection, Gene Expression, Enzyme-linked Immunosorbent Assay

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Changes in STAT1 phosphorylation and nuclear translocation levels in CRFK-PHBLV-N cells after ursodeoxycholic acid treatment. ( A ) STAT1 Western blot results in CRFK-PHBLV-N cells. ( B ) Grayscale analysis of p-STAT1/STAT1 protein in CRFK-PHBLV-N cells. ( C ) CRFK-STAT1 IFA results in PHBLV-N cells. ( D ) STAT1 fluorescence intensity analysis in CRFK-PHBLV-N cells. ** P < 0.01; *** P < 0.001; and **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Phospho-proteomics, Translocation Assay, Western Blot, Fluorescence

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Changes in TLR3 protein, IRF3 phosphorylation, and nuclear translocation levels in CRFK-PHBLV-N cells after ursodeoxycholic acid treatment. ( A ) Graph of TLR3 and IRF3 Western blot results in CRFK-PHBLV-N cells. ( B ) Graph of TLR3 protein grayscale analysis in CRFK-PHBLV-N cells. ( C ) Grayscale analysis plot of p-IRF3/IRF3 protein in CRFK-PHBLV-N cells. ( D ) Graph of IRF3 IFA results in CRFK-PHBLV-N cells. ( E ) Graph of IRF3 fluorescence intensity analysis in CRFK-PHBLV-N cells. ** P < 0.01; *** P < 0.001; and **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Phospho-proteomics, Translocation Assay, Western Blot, Fluorescence

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Changes in MX1 and ISG15 protein levels in CRFK-PHBLV-N cells after ursodeoxycholic acid treatment. ( A ) Western blot results of MX1 and ISG15 in CRFK-PHBLV-N cells. ( B ) Grayscale analysis of MX1 protein in CRFK-PHBLV-N cells. ( C ) Grayscale analysis of ISG15 protein in CRFK-PHBLV-N cells. ISG15 protein grayscale analysis graph in CRFK-PHBLV-N cells. * P < 0.05; ** P < 0.01; *** P < 0.001; and **** P < 0.0001.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques: Western Blot

Journal: Microbiology Spectrum

Article Title: Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon

doi: 10.1128/spectrum.03633-25

Figure Lengend Snippet: Diagram of UDCA anti-FIPV mechanism through JAK-STAT signaling pathway.

Article Snippet: Ursodeoxycholic acid was selected for this study and was provided by MedChemExpress, a life science reagent service provider.

Techniques:

Journal: Yonsei Medical Journal

Article Title: Cholecystectomy for Prevention of Recurrence after Endoscopic Clearance of Bile Duct Stones in Korea

doi: 10.3349/ymj.2016.57.1.132

Figure Lengend Snippet: Patient Characteristics and ERCP Findings at Initial ERCP

Article Snippet: Possible risk factors for the recurrence of CBD stones including history of cholecystectomy, previous Billroth-II operation, bile duct diameter, stone size, number of stones, stone composition, periampullary diverticulum, mechanical lithotripsy, multiple ERCP sessions, and use of ursodeoxycholic acid (UDCA) and/or Rowachol® (Rowa Pharmaceuticals Ltd., Newtown, Bantry, Co. Cork, Ireland) medication were analyzed.

Techniques:

Journal: Yonsei Medical Journal

Article Title: Cholecystectomy for Prevention of Recurrence after Endoscopic Clearance of Bile Duct Stones in Korea

doi: 10.3349/ymj.2016.57.1.132

Figure Lengend Snippet: Univariate Analysis of Risk Factors for Recurrent Bile Duct Stones in Terms of Patient Clinical Characteristics and ERCP Findings between the Recurrence Group and the Non-Recurrence Group at Initial ERCP

Article Snippet: Possible risk factors for the recurrence of CBD stones including history of cholecystectomy, previous Billroth-II operation, bile duct diameter, stone size, number of stones, stone composition, periampullary diverticulum, mechanical lithotripsy, multiple ERCP sessions, and use of ursodeoxycholic acid (UDCA) and/or Rowachol® (Rowa Pharmaceuticals Ltd., Newtown, Bantry, Co. Cork, Ireland) medication were analyzed.

Techniques: